8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): February 14, 2007

                         Renhuang Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)

                                     Nevada
                 (State or Other Jurisdiction of Incorporation)


                  0-24512                       88-1273503
          (Commission File Number) (IRS Employer Identification Number)

                    No. 281, Taiping Road, Taiping District,
                      Harbin, Heilongjiang Province, 150050
                                   P. R. China
                    (Address of Principal Executive Offices)

                                +86-451-5762-0378
              (Registrant's Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


- --------------------------------------------------------------------------------








Item 7.01   Regulation FD Disclosure.
            -------------------------

 On February 14, 2007, Renhuang Pharmaceuticals, Inc (the "Company") issued a
press release, a copy of which is attached as Exhibit 99.1 to this report and
is being furnished to the SEC and shall not be deemed "filed" for any purpose.



Item 9.01   Financial Statements, Pro Form Financial Information and Exhibits.
(c)         Exhibits.


                                    EXHIBITS

Exhibit                           Description
- -------                           ----------------------------------------------
99.1                              Press Release dated February 14, 2007.


- --------------------------------------------------------------------------------










                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    Renhuang Pharmaceuticals, Inc.


Date: February 14, 2007             By: /s/ Shaoming Li
                                        ----------------------------------------
                                        Shaoming Li
                                        Chief Executive Officer and President


- --------------------------------------------------------------------------------

EX-99.1

                                                                    Exhibit 99.1

Renhuang Pharmaceuticals Announces Results for the Six Month Transition Period
May 1 - October 31, 2006: Net Income More Than Doubled Compared to the Same
                       Period of the Prior Year

    Highlights:

    --  Net income of $4.40 million more than doubled compared to the
        same period of the prior year

    --  Revenues of $12.25 million remained strong compared to the
        revenues of $11.72 million for the same period of the previous
        year

    --  Earnings per share for six months $ 0.125

    HARBIN, China--(BUSINESS WIRE)--Feb. 14, 2007--Renhuang
Pharmaceuticals, Inc. (or "the Company", Stock symbol: RHGP.OB), a
leading provider of natural health care products in the People's
Republic of China (PRC), filed its first 10K since it went public in
September 2006 and announced its results for the transition period of
May 1 to October 31, 2006, which is the second half of the Company's
2006 fiscal year.



Key Figures
- ----------------------------------------------------------------------
                        May 1 - Oct. 31    May 1 - Oct. 31      YoY%
                             2006               2005           change
- ----------------------------------------------------------------------
Revenue                    $12,247,489         $11,721,151          4%
- ----------------------------------------------------------------------
Net Income                  $4,404,578          $1,768,776        149%
- ----------------------------------------------------------------------
Net Profit Margin (%)               36%                 15%
- ----------------------------------------------------------------------


    For the six month period ending October 31, 2006, the Company
generated a net income of $4.40 million, which more than doubled
compared to the $1.77 million net income generated for the same period
of the prior year. The significant year-over-year growth of earnings
was partly driven by lower operating expenses, seasonal adjustments
and some financial restructuring related to the reverse merger.

    Basic earnings per common share for the six month period were
$0.125 per share. The number of shares issued and outstanding as of
the date of the report was approximately 35 million.

    Revenues for the six month period from May 1 to October 31, 2006
remained strong, reaching $12.25 million compared to $11.72 million
for the same period of last year. The increase was primarily driven by
continued strong sales in Acanthopanax medical products, Shark Power
Health Care products, and Traditional Medical products, which
respectively contributed 53%, 12%, and 35% to the total revenues.

    Given the fact that the six months ended October 31, 2006 was the
Company's first reporting period and the Company only conducted the
current operations from May 1, 2006 through October 31, 2006, a
financial projection based only on the current and the prior year
results may not be a good indication of the Company's future
performance. Due to seasonality, current six month revenues of $12.25
million may not be indicative of the revenues in future periods. The
financial comparison and projection will be more indicative after the
Company has conducted its current operations for a few more periods.

    Commenting on the six month results, Renhuang's Chairman Mr. Li,
Shaoming said, "Renhuang Pharmaceuticals delivered strong results for
its first six month period as a public company. Our sales remained
strong in each of our major product lines and our earnings more than
doubled from the same period of last year. The strong results reflect
our solid strategy, our success in executing the strategy, and our
efforts in achieving excellence in operation, manufacturing, and R&D."

    Outlook

    Overall, the Company is very optimistic about growing its earnings
and revenues over time. With several new products recently launched
and its traditional products in strong demand, the Company is
confident that earnings and revenues will grow continuously. The
Company also expects to expand its market internationally as consumers
around the world are seeking alternative medicines and as Renhuang's
products are increasingly sought after due to growing awareness of the
efficacy of natural health care products and Chinese herbal medicine.

    "We are very pleased to see our earnings grow significantly year
over year, with a net income of $4.4 million generated in this first
six month period since we became a public company," said Mr. Li,
Shaoming. "In the light of the current results, we believe in a
continued growth and profitability given our highly sought after
products, strong R&D program, superior manufacturing capability, and
large distribution network. We expect to continue to deliver high
growth in our business and we are committed to looking for every
opportunity to create value for our shareholders. For the fiscal year
2007 we expect revenues to be between $ 35 to $ 40 million and net
profits to be between $ 10 to $ 12 million."

    Details of the Company's financial data for the transition period
from May 1 - October 31, 2006, are available in the Company's Current
Report 10K dated and filed with the Securities and Exchange Commission
on February 13, 2007.

    About Renhuang Pharmaceuticals, Inc.:

    Renhuang Pharmaceuticals is a leading bio-pharmaceutical company
located in Harbin in the Heilongjiang Province in Northeast China.
Renhuang is primarily engaged in the research, production, and sales
of bio-pharmaceutical products in Mainland China. The Company's main
products are Siberian ginseng, shark liver oil and several other
traditional medical products. It is estimated that 70% of China's
natural supply of Siberian Ginseng is currently controlled by the
Company.

    The company also anticipates approval within six to nine months by
State Food and Drug Administration ("SFDA") for up to five of its new
Monoclonal Antibody Reagent Box series products. These products are
60% more reliable than those from its competitors and also adhere to
"Good Manufacturing Practices", or "GMP". Moreover, the company is in
the process of building its own immune system research and development
function. Overall, the company is able to achieve significant cost
savings compared to most of its competitors, who purchase their raw
materials from third parties.

    Over 2000 sales agents are employed in seventy sales centers
across twenty-four districts and cover over 50% of the greater China
area and 80% of its population, including the most populous and
developed Eastern China. The Company employs over 50 people in its R&D
department, a number of which are well recognized and respected
pharmaceutical professors and research scientists from National Navy
Pharmaceutical Research Center, Beijing Ellionbio Research Center and
other well known institutions. State of the art research and
production facilities using the latest technologies are currently used
by the Company's scientists to develop new and innovative areas,
including antiseptic and immune system products and Diagnostic kits.
RHGP-G

    Safe Harbor Statement

    This press release contains certain statements that may include
'forward-looking statements' as defined in the Securities Act of 1933,
and the Securities Exchange Act of 1934. All statements, other than
statements of historical facts, included herein are 'forward-looking
statements.' Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks and uncertainties, and these expectations
may prove to be incorrect. You should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this press release.

    The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of a
variety of factors, including those discussed in the Company's
periodic reports that are filed with and available from the Securities
and Exchange Commission. All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified
in their entirety by these factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.

    CONTACT: Christensen, New York
             Christy Shue, 917-576-2209
             cshue@ChristensenIR.com
             or
             Renhuang Pharmaceuticals Inc, China
             Gina Gao, 0086-451-57620378
             Fax: 0086-451-57606414
             gs@renhuang.com